Lv3
234 积分 2024-05-23 加入
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
1小时前
待确认
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer
1小时前
已完结
Preventing central nervous system metastases in non-small cell lung cancer
2小时前
已完结
Prevalence, therapeutic approaches, and survival rates of brain metastases in non-small cell lung cancer: a multi-institutional claims-based study from 2014 to 2024
2小时前
已完结
Strategies to prevent brain metastasis
2小时前
已完结
脑转移瘤的治疗现状
2小时前
求助中
Real-world incidence, prevalence, and clinical impact of brain metastases in patients with ALK-positive metastatic non–small cell lung cancer treated with first-line ALK tyrosine kinase inhibitors
4小时前
已完结
Based on the CROWN Findings, Lorlatinib Should Be the Preferred First-Line Treatment for Patients With Advanced ALK-Positive NSCLC
4小时前
已完结
First-Line Lorlatinib Versus Crizotinib in Asian Patients With Advanced ALK-Positive NSCLC: Five-Year Outcomes From the CROWN Study
18天前
已完结
皖公网安备34019202002308
